Pharmacogenomics in 2018: Current Applications and Future Opportunities

Presentation

View the Archived Webinar

  Video length: 1 hour 2 minutes

Overview

While evidence for the influence of genetics on drug response has been accumulating for decades, the field of pharmacogenomics has evolved rapidly in recent years. This webinar will provide an overview of evidence-based applications of pharmacogenomics, share recent advances, and discuss the clinical utility of new panels and single-gene tests.
 

Presenters

Image of Ann Moyer, M.D., Ph.D.Ann Moyer, M.D., Ph.D.
Assistant Professor of Laboratory Medicine and Pathology
Mayo Clinic College of Medicine and Science
Division of Clinical Biochemistry
Mayo Clinic, Rochester, Minnesota
 

 

 

Image of John Logan Black, M.D.John Logan Black, M.D.
Professor of Psychiatry
Mayo Clinic College of Medicine and Science
Division of Clinical Biochemistry
Mayo Clinic, Rochester, Minnesota

 

 

 

Learning Objectives

  • Summarize basic concepts of genetics and pharmacogenomics.
  • Describe testing modalities currently available, including limitations.
  • Explain evidence-based applications of pharmacogenomics testing.
  • List appropriate uses of single-gene and panel testings.
  • Recommend new tests and tools that increase the utility of pharmacogenomics.

 

Intended Audience

This webinar is designed for any provider who prescribes drugs with pharmacogenomic associations (e.g., cardiologists, oncologists, psychiatrists, neurologists, primary care physicians including internists and family care practitioners, etc.) as well as pathologists, laboratory directors, and laboratory sendout coordinators.

 

Level of instruction

Intermediate

 

Faculty Disclosure

Course director(s), planning committee, faculty, and all others who are in a position to control the content of this educational activity are required to disclose all relevant financial relationships with any commercial interest related to the subject matter of the educational activity. Safeguards against commercial bias have been put in place. Faculty members also will disclose any off-label and/or investigational use of pharmaceuticals or instruments discussed in their presentations. Disclosure of this information will be published in course materials so those participants in the activity may formulate their own judgments regarding the presentations.

National Physician Payment Transparency Program

Mayo Medical Laboratories is not an applicable manufacturer or applicable group purchasing organization (GPO). (GPOs, per the Centers for Medicare & Medicaid Services, and this program do not trigger any reporting requirements pursuant to Open Payments [Sunshine Act] legislation.)

 

Note: No credit is offered for this Specialty Testing presentation.

MCL Education

MCL Education

This post was developed by our Education and Technical Publications Team.